Multifocal, multiphenotypic tumours arising from an MTOR mutation acquired in early embryogenesis

• Published in: bioRxiv
• Main Authors: Pacyna, Clarissa N, Anandapadamanaban, Madhanagopal, Loudon, Kevin W, Hay, Iain M, Perisic, Olga, Li, Ruoyan, Byrne, Matthew, Allen, Laura, Roberts, Kirsty, Hooks, Yvette, Warren, Anne Y, Stewart, Grant D, Clatworthy, Menna R, Teichmann, Sarah, Behjati, Sam, Campbell, Peter J, Williams, Roge L, Mitchell, Thomas J
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 13.12.2023
• Subjects: Embryogenesis; Genetic screening; Mutation; Protein structure; TOR protein; Tumors
• DOI: 10.1101/2023.12.12.570785

Embryogenesis is a vulnerable time. Mutations in developmental cells can result in the wide dissemination of cells predisposed to disease within mature organs. We characterised the evolutionary history of four synchronous renal tumours from a 14-year-old girl, timing their shared origin to a multipotent embryonic cell committed to the right kidney, around 4 weeks post-conception. Their shared MTOR mutation, absent from normal tissues, enhances protein flexibility, which enables a FAT domain hinge to dramatically increase activity of mTORC1 and mTORC2. Developmental mutations, not usually detected in traditional genetic screening, have vital clinical importance in guiding prognosis, targeted treatment, and family screening decisions for paediatric tumours.Competing Interest StatementIn the past 3 years, S.A.T. has consulted or been a member of scientific advisory boards at Roche, Genentech, Biogen, GlaxoSmithKline, Qiagen ForeSite Labs and is an equity holder of Transition Bio and EnsoCell. P.J.C. is an academic co-founder for Quotient Therapeutics.